# Zentalis Pharmaceuticals Reports 15.8-Month Median Overall Survival in DENALI Part 1b

> Zentalis reported a 15.8-month median overall survival in Cyclin E1-positive platinum-resistant ovarian cancer patients on azenosertib monotherapy.

- Published: 2026-10-18T23:07:42+00:00
- Section: Research & Clinical Trials
- Author: News Desk
- URL: https://newsforagent.com/news/2026-10-18/zentalis-denali-interim-survival-signal
- Source: [TradingView](https://www.tradingview.com/news/tradingview:d6aa3729f9ac2:0-zentalis-pharmaceuticals-inc-zntl-reports-interim-os-signal-in-denali-part-1b/)

## Key takeaways

- Zentalis reported a median overall survival of 15.8 months in Cyclin E1-positive platinum-resistant ovarian cancer patients treated with azenosertib monotherapy.
- The DENALI Part 1b data will be presented as a rapid oral presentation at ESMO Congress 2026 on October 23, 2026.
- Zentalis plans to enroll Cyclin E1-positive patients in DENALI Part 2, while the ASPENOVA Phase 3 confirmatory trial continues.

[Zentalis Pharmaceuticals](https://akta.pro/company-profiles/0000ryi/zentalis-pharmaceuticals) reported interim overall survival data from DENALI Part 1b in platinum-resistant ovarian cancer, with a median overall survival of 15.8 months in Cyclin E1-positive patients treated with azenosertib monotherapy. The company said the data will be presented as a rapid oral presentation at ESMO Congress 2026 on October 23, 2026. The details were reported by [TradingView](https://www.tradingview.com/news/tradingview:d6aa3729f9ac2:0-zentalis-pharmaceuticals-inc-zntl-reports-interim-os-signal-in-denali-part-1b/).

## Zentalis's DENALI Part 1b Survival Data

The abstract states Cyclin E1 is a highly selective predictive biomarker, and that overall survival compares favorably to historical chemotherapy in Cyclin E1-positive patients. Zentalis plans to enroll Cyclin E1-positive patients in DENALI Part 2. The ASPENOVA Phase 3 confirmatory trial is ongoing.

Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company developing azenosertib, an investigational oral WEE1 kinase inhibitor for Cyclin E1-positive platinum-resistant ovarian cancer, paired with a proprietary companion diagnostic and registration-intent Phase 2 and Phase 3 trials underway. The company is based in New York and was founded in 2014.

## Zentalis's Azenosertib Trial and Funding Records

According to akta.pro [company records](https://akta.pro/company-data), Zentalis initiated the ASPENOVA Phase 3 confirmatory trial of azenosertib in Cyclin E1-positive platinum-resistant ovarian cancer, with the first patient dosed. The same records show a cash position of $211.8 million as of Q1 2026, providing runway into late 2027, and a 2026-08 post ipo equity round of $92.6 million. The company's total funding stands at $989.2 million.

## Zentalis's Earlier 2026 Developments

In August 2026, Zentalis announced a proposed underwritten public offering of its common stock and pre-funded warrants to raise capital for clinical trials and general corporate purposes, according to Yahoo. The company released quarterly earnings results on August 6, 2026, reporting a loss of $0.59 per share, which missed the consensus estimate of $0.45 per share by $0.14, according to Markets Daily. In September 2026, Wells Fargo initiated coverage on Zentalis with an equal-weight rating and a $5.00 price target, according to Markets Daily.

## Zentalis's ESMO Presentation Date

The DENALI Part 1b data will be presented at ESMO Congress 2026 on October 23, 2026.

## Companies in this story

- [Zentalis Pharmaceuticals company profile](https://akta.pro/company-profiles/0000ryi/zentalis-pharmaceuticals) · website: https://www.zentalis.com

---
News for Agent · https://newsforagent.com/llms.txt